Previously submitted to: Journal of Medical Internet Research (no longer under consideration since Jan 16, 2025)
Date Submitted: Jul 17, 2024
Open Peer Review Period: Jul 23, 2024 - Sep 17, 2024
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Randomized Controlled Trial of a Digital Therapeutics System for Treating New-onset Mild Hypertension
ABSTRACT
Background:
Hypertension is the single most significant modifiable risk factor for all-cause morbidity and mortality worldwide.Lifestylechanges are the cornerstone of prevention and treatment of hypertension，Traditional lifestyle intervention depends on the hospital visit follow-up, patients with poor execution and poor compliance.However, the therapeutic effect of LIAN digital therapy with Internet technology in patients with mild hypertension is not yet established.
Objective:
We aim to evaluate the therapeutic efficacy of LIAN digital therapeutics in patients with new-onset mild hypertension who did not receive antihypertensive medication.
Methods:
This randomized controlled clinical trial included 1525 individuals with new-onset mild hypertension who were admitted to our Health Management Medicine Center between January 2022 and March 2023. They were randomly assigned 1:1 to the digital therapeutics group (n=756) or the control group (n = 769). The primary efficacy endpoint was the mean change in office blood pressure (BP) from baseline to 12 weeks. The key secondary efficacy endpoints were the mean changes in lipoprotein indices and lifestyle factors from baseline to 12 weeks.
Results:
The mean office BP decreased from 142.03 (SD 8.05)/90.39 (SD 5.69) to 136.19 (SD 10.60)/85.44 (SD 7.62) mmHg in the digital therapeutics group and from 141.91 (SD 7.25)/90.28 (SD 5.57) to 139.78 (SD12.33)/89.00 (SD 8.84) mmHg in the control group, with a mean difference in systolic BP and diastolic BP of –5.85 mmHg (95% CI –6.64 to –5.05 mmHg; P<0.001) and –4.95 mmHg (95% CI –5.50 to –4.40 mmHg; P<0.001), respectively. From baseline to 12 weeks, office BP control (<140/90 mmHg) was achieved in 423 (56.0%) patients in the digital therapeutics group and 308 (40.1%) patients in the control group (P<0.001). At 12 weeks, no group differences existed in high-density lipoprotein cholesterol (P=0.082), total cholesterol (P=0.055) or low-density lipoprotein (P=0.222) concentrations. However, changes in the total cholesterol/high-density lipoprotein cholesterol ratio and lifestyle factors were statistically significant (P<0.001). At 12 weeks, there were significant differences in lifestyle factors, including limiting oil consumption (P<0.001), limiting salt consumption (P<0.001), smoking status (P<0.001), drinking status (P<0.001), and exercise status (P<0.001), between the digital therapeutics group and the control group.
Conclusions:
Our study confirmed the superiority of digital therapeutics for improving BP and lifestyle factors in people with new-onset mild hypertension without antihypertensive medications.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.